secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2024-01-17T23:59:59+00:00
Accession:  0001159036-24-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme prelim FY2023 revenue $827-832M; GAAP EPS $2.18-2.21
-------------------------------------------------------------

- Revenue estimated $827-832M; royalties $445-450M for FY2023.
- Net income $292-297M; EBITDA $435-440M; adjusted EBITDA $425-430M.
- GAAP diluted EPS $2.18-2.21; non-GAAP diluted EPS $2.77-2.80.
- Preliminary unaudited estimates subject to completion of year-end close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903624000003/0001159036-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903624000003/halo-20240117.htm
  HTML page:      https://secwatch.observer/filing/0001159036-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer